Q4 2023

Source filing unavailable

Q4 2023 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$276.01K

derivedno prior Q4 2022 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$187,851—

Same quarter

no prior Q4 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cannabis Bioscience International Holdings, Inc. · CIK 1411057 · Engraved from SEC EDGAR